Spectral Medical Inc. develops and commercializes products for treating septic shock and renal disease. The company shows strong profitability with a gross margin of 63.3% and an impressive EBITDA margin of 338.5%, indicating effective cost management. However, its liquidity ratios are concerning, with a current ratio of 0.04 and a quick ratio of 0.03, suggesting potential short-term financial challenges. While high margins are promising, the low market price of $1.06 raises questions about investor confidence and overall valuation.
Loading financial metrics...
Company has $803K in cash but burned $2.5M last quarter. At this burn rate, only 0.3 quarters of runway remain without additional financing.
Company posted a loss of $-35.8M over the last year, representing 1392.0% of revenue.
Debt of $25.7M is 32.0x the company's cash position of $803K.
Operating cash flow has been negative for 3 consecutive quarters, burning $9.8M over the last year.
Gross margin expanded by 11.3 percentage points, indicating improved pricing power or cost efficiency.
Operating margin expanded by 192.4pp, demonstrating strong operational leverage.
Both gross margin (+11.3pp) and operating margin (+192.4pp) are expanding simultaneously, indicating the company is scaling profitably.
Exceptional gross margin of 71.1% indicates strong pricing power and competitive moat.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Based on 2026-Q2 (June 30, 2026)